- subjects who are outpatients or inpatients
- written informed consent obtained (signed by the subject or the subject's legally
acceptable representative)
- traumatic spinal cord injury of at least 1 year duration with a nonprogressive, i.e.,
chronic, stage of at least 6 months duration
- At-level neuropathic pain: spontaneous or evoked pain with neuropathic features
(sharp, shooting, electric or burning pain sensation) in the region of sensory
disturbance in a segmental pattern and located within two dermatomes above or below
the level of spinal cord injury
- Below-level neuropathic pain: spontaneous or evoked pain with neuropathic features
(sharp, shooting, electric or burning pain sensation) in the region of sensory
disturbance located at least three dermatomes below the level of spinal cord injury
- spinal cord injury (subjects with central pain and musculoskeletal pain must be able
to make a distinction between the two)
- subjects who have previously not responded to 300 mg/day pregabalin: a non-responder
is defined as a subject who has a reduction in pain score of less than 30% from
baseline